Be the surgeon at the intersection of medication and surgery
GLP-1 medications are now the first step for many patients with mild-to-moderate obesity. Surgery remains the treatment of choice for severe obesity, for patients who don't reach goal on medication, and for plateau or weight regain. The directory is where patients move between both pathways.
Why this matters now
Modern obesity care is no longer 'medication or surgery' — it's a two-way pathway. Severe obesity, medication intolerance, inadequate response, plateau, and post-bariatric weight regain all create surgical consultation moments. Each one is a patient looking for a surgeon.
The numbers
−34%
global bariatric volume 2022–2025 — case mix shifted, not the indication
JAMA Surgery, May 2026
BMI ≥40
where surgery remains the treatment of choice
ASMBS 2025
Two-way
the modern medication ↔ surgery pathway
ASMBS 2025 guidance
Highest
MASLD prevalence: post-bariatric cohort
Clinical literature
Data view
The numbers behind the pitch
Bariatric surgery vs GLP-1 prescriptions — same 3-year window
Source: JAMA Surgery, May 2026; PBS dispensing data 2022–2025
GLP-1 prescriptions +140% while bariatric surgery −34% in the same 3-year window. Mild-to-moderate cases now start with medication; severe obesity, inadequate response, and weight regain still reach surgery.
Australian bariatric procedure volumes — first decline since 2020
Source: Obesity Surgery, Feb 2026; MBS procedure data
Decline temporarily masked by 2023-24 GLP-1 supply shortages. The cohort reaching surgery is now smaller in number but more clinically complex on average.
Clinical context
The case mix has shifted — surgery's role hasn't
JAMA Surgery (May 2026) reports a 34% global decline in bariatric procedure volume from 2022 to 2025. The reading isn't that surgery is being displaced — it's that mild-to-moderate obesity patients are increasingly trialling GLP-1s first. The patients now reaching surgical consultation are more clinically complex on average: severe obesity (BMI ≥40 with comorbidities), medication non-response, intolerance, or weight regain after initial GLP-1 success. Surgery remains the treatment of choice for these cohorts.
The Australian picture
Obesity Surgery (February 2026) confirms the Australian surgical decline was artificially slowed by 2023–24 GLP-1 supply shortages. With supply normalised, AU volumes are following the global trajectory. The strategic implication for your practice is to be discoverable to a higher-intent, more complex referral population — not to a generic obesity cohort that no longer exists.
The two-way pathway
Patients move between pharmacotherapy and surgery in both directions: GP → GLP-1 trial → inadequate response / intolerance → surgical consultation; or bariatric surgery → years later → weight regain → GLP-1 + surgical review. ASMBS 2025 guidance explicitly endorses GLP-1 use pre-operatively (bridge to surgery), peri-operatively in selected cases, and post-operatively for weight regain — surgeons fluent in the medication landscape are the ones patients (and GPs) are actively looking for.
Why post-bariatric monitoring still matters
Post-bariatric patients have the highest MASLD prevalence of any clinical group. Whether or not they're on a GLP-1, this cohort needs structured liver and metabolic monitoring — and your practice is the natural surgical home for that follow-up.
Evidence base
What the literature says, in one place
Bariatric procedure volume down 34% globally between 2022 and 2025 — the case mix has shifted toward more complex / severe presentations.
JAMA Surgery, May 2026
ASMBS 2025 guidance endorses GLP-1 use as a bridge to surgery, in selected peri-operative contexts, and for weight regain post-bariatric.
ASMBS 2025
Australian decline temporarily slowed by 2023–24 supply shortages; now following global trajectory as supply normalises.
Obesity Surgery, Feb 2026
Surgery remains the treatment of choice for severe obesity (BMI ≥40 with comorbidities) and for patients with inadequate response to or intolerance of pharmacotherapy.
Post-bariatric patients have the highest MASLD prevalence of any clinical group — liver monitoring is indicated for every post-bariatric patient regardless of GLP-1 use.
What your patients are searching
Patients searching 'weight loss surgery vs Ozempic', 'bariatric surgeon near me', 'GLP-1 plateau' and 'weight regain after surgery' are looking to compare and move between pathways — not pick a side. The directory is built to be that bridge.
What a free profile gets you, as a bariatric surgeon
Be the surgeon GLP-1 patients reach when medication isn't enough or isn't tolerated.
Free profile listing pre- and post-bariatric care, peri-operative GLP-1 management, and revision options.
Verified surgeon badge once we confirm AHPRA + RACS credentials.
Built for clinicians, not marketers
We're an Australian-built directory focused on GLP-1 monitoring pathways. No booking fees, no commission, no upsells that gate basic functionality.
Free profile
SEO-optimised profile page that ranks in Google for your suburb + service.
Patient enquiry inbox
Enquiries from patients land in one simple inbox. Respond on your terms.
Demand analytics
See how many patients searched your suburb, viewed your profile, and called.
Verified badge
Once we verify credentials, you get priority placement and a Verified marker.
Claim your free profile in under 5 minutes
No credit card. No lock-in. Visible to patients in your suburb the moment you publish.